MYC dysregulation appeared to be tissue-specific tissue during tumorigenesis; MYCN was described to be aberrantly expressed in neuronal or neuroendocrine tumors, and more recently, in ovarian cancer, prostate cancer, and in a subset of breast cancer with poor prognosis [40,41,42]. This evidence concerns the gene MYCN and prostate cancer.